RT Journal Article SR Electronic T1 Radioiodine Therapy Induces Dose-Dependent In Vivo Oxidation Injury: Evidence by Increased Isoprostane 8-Epi-PGF2α JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 1254 OP 1258 VO 43 IS 9 A1 Wolfram, Roswitha M. A1 Budinsky, Alexandra C. A1 Palumbo, Barbara A1 Palumbo, Renato A1 Sinzinger, Helmut YR 2002 UL http://jnm.snmjournals.org/content/43/9/1254.abstract AB 131I is the treatment of choice for differentiated thyroid cancer and hyperthyroidism. A relationship between low-density lipoprotein oxidation and radioiodine therapy-related side effects, consequently inducing increased formation of 8-epi-prostaglandin F2α (PGF2α) in situ, has recently been reported by several investigators. Isoprostanes, among them 8-epi-PGF2α, have been associated with increased oxidation injury due to various pathologic conditions in vivo. The aim of this study was to investigate the possible induction of oxidative stress as a consequence of 131I therapy. Methods: 8-epi-PGF2α was examined in plasma, serum, and urine in 42 patients undergoing radioiodine treatment of hyperthyroidism or thyroid cancer. The 8-epi-PGF2α levels were analyzed daily for 1 wk and thereafter at different points up to 12 wk after treatment. Results: The isoprostane levels showed an increase after application of radioiodine in all investigated compartments. The effect was significantly higher and longer lasting after higher-activity therapy (2,960 or 7,400 MBq) than after lower-activity therapy (185 or 740 MBq). Conclusion: These findings document a significant, dose-dependent in vivo oxidation injury as a consequence of therapeutic radioiodine application to the salivary gland.